E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mild to moderate psoriasis |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Change in the Psoriasis area and severity index between baseline and end of feeding. |
|
E.2.2 | Secondary objectives of the trial |
The secondary end point= Psoriasis Disability Index{PDI} Patients Global Assessment,{PGA} Physician,s Global Assessment Index.{PGAI}
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subjects diagnosed with mild to moderate psoriasis as defined by the clinician 2. Has a Psoriasis Area and Severity Index{PSAI} of < than 20.
3. Male or Female subjects 4. Aged between 18-60 years of age 5. Non-pregnant Female and must be agree to use adequate method of contraception during the study 6. Is capable of giving written informed consent prior to study entry. 7. Be willing to refrain from taking dietary supplements or other foods that contain fermented live bacteria within 1 month prior to treatment and during the study. 8. Have not participated in a clinical drug study or used an investigational new drug during the past previous 30 days. 9. Clinical chemistry and haematology results from Visit 1 are within normal limits. 10. Be willing to refrain from using any topical psoriatic cream 2 weeks prior to treatment and during the study.
|
|
E.4 | Principal exclusion criteria |
1. Are less than 18 years of age, and not more than 60 years of age. 2. History of sensitivity to lactose (e.g., lactose intolerance) or other dairy products; 3. Pregnant or lactating females. 4. Consume other probiotics within 2 weeks of treatment start 5. Being treated with steroids 2 weeks prior to entry 6. Evidence of other inflammatory skin disease that may confound the evaluation of psoriasis. 7. Has had systemic antipsoriatic treatment or PUVA therapy within the previous 4 weeks. 8. Subject who has had UVB therapy within the previous 2 weeks.
9. Diseases of the gastrointestinal tract, liver, pancreas and bilary tree [e.g. gastritis, symptomatic gallstones, duodenal ulcer, gastroenteritis, diverticulitis]. Exceptions include haemorrhoids, hiatus hernia and asymptomatic gallstones. 10. History of major gastric, hepatic, pancreatic or intestinal surgery or perforation, excluding cholecystectomy, appendectomy, haemorrhoidectomy or polypectomy. 11. Recent unexplained rectal bleeding and/or significant unexplained weight loss. 12. Antibiotic use within one month prior to Visit 1, 13. Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, immunological,) or a condition, which contraindicates, in the investigators judgement, entry to the study. 14. Patients with Diabetes Mellitus. 15. Individuals who, in the opinion of the investigator, are considered to be poor clinical attendees or unlikely for any reason to be able to comply with the trial. 16. Subjects currently receiving treatment involving experimental drugs. 17. If a subject has been in a recent experimental trial, must be not less than 30 days prior to this study. 18. Have a concomitant end-stage organ disease eg, cardiovascular, pulmonary, hepatic and renal, which, in the Investigator’s judgment, contraindicates participation in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary efficacy endpoint = Change in the Psoriasis area and severity index between baseline and end of feeding. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
When adequate numbers as per statistician have completed the trial and or if the patient has been excluded from the trial as per protocol |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |